User:Adam Osseiran/sandbox

Professor Peter Klinken (born XY ABCD 1953) PhD FFFFFFFFFFF is an Australian medical researcher and academic. In 2014 he was appointed as Chief Scientist of Western Australia, providing advice to the Premier and Minister for Science of Western Australia.

One of his favourite sayings is “A stopped clock is right twice a day”. In an interview in 2016, Professor Klinken said: it is important to listen to everybody; you can never tell where some gems come from. Never be arrogant enough to think you know it all, because a stopped clock is right twice a day.

Early life and education

Peter Klinken was born on XY ABCD 1953 in Singapore. He completed his secondary schooling at He …. University of Western Australia. He graduated…. His research thesis……

Achievements

Professor Klinken played a key role in establishing the Western Australian Institute for Medical Research - WAIMR Institute in 1998. He then spear-headed the development of the Harry Perkins Institute of Medical Research with two state-of-the-art medical research facilities worth $200m, Perkins North (at the QEII Medical Centre) and Perkins South (in Fiona Stanley Hospital). From 2002 to 2014 during his tenure as Executive Director of the Perkins Institute the Institute grew from 63 to over 250 researchers and staff, and established a number of spin-off companies including Linear Clinical Research, an early Phase clinical trials facility. Under his stewardship, the Perkins Institute attracted world-class national and international researchers to the State and made numerous acclaimed medical discoveries.

Academic career

Professor Klinken obtained his PhD in Biochemistry from the University of Western Australia in 1982, and between 1984 and 1986 he was a Fogarty International Fellow at the US National Institutes of Health in Washington. He then worked as an NHMRC Post-doc fellow at the Walter and Eliza Hall Institute of Medical Research in Melbourne. In 1989 he returned as an academic to the University of Western Australia, where he received 2 “Excellence in Teaching” Awards. In 1994 he was appointed Professor of Clinical Biochemistry based at Royal Perth Hospital, and in 2000 he became Director of Research at Royal Perth Hospital working on the regulation of red blood cell formation and ability of leukemia cells to develop different features and functions. Professor Klinken’s research interests encompass the regulation of red blood cell formation, and the ability of leukemic cells to develop different features and functions. He has a long-standing interest in identifying genes, which when altered can cause leukemia and other cancers. During his career on genetic research relating to cancer and anaemia, he discovered in 2004 the gene known as HLS5 which suppresses the growth of tumours.

Honours and recognitions

•	2002 - Paul Harris Fellow of The Rotary Foundation •	2008 - Western Australian Citizen of the Year Award •	2012 - Ernst and Young Social Entrepreneur of the Year •	2015 - Fellow of the Australian Academy of Health and Medical Sciences •	2016 – Fellow of the Australian Academy of Technological Science and Engineering •	2016 – Innovate Australia Award for Outstanding Contribution to Western Australian Science, Technology & Innovation

Professional Responsibilities and Engagements

Professor Klinken has been a member of the Board of the Cancer Research Trust since 2009, and is on the Medical Research Advisory Committee of the Australian Cancer Research Foundation, as well as the Scientific Advisory Committee of the Children’s Cancer Institute of Australia and the Lions Eye Institute. Between 1992 and 2005 he provided support to the National Health and Medical Research Council of Australia in a variety of roles, and served on the Council of Scotch College, Perth (2003-2008) as well as the Board of the Diabetes Research Foundation (2004-2008).

Professor Klinken was Regional Editor of the International Journal of Biochemistry and Cell Biology (1994-2004) and was a member of the Editorial Board of Experimental Haematology (2000-2004). He was an inaugural invited member of the International Molecular Biology Network, and has participated in numerous institutional reviews.

‪Personal life‬‬

Peter Klinken is married with a daughter and 2 sons.

References‬‬

1.	Interview with Geoff Hutchison, 720 ABC Perth (11 June 2014) 2.	10 minutes on leadership, Business News (17 August 2016) 3.	Publications‬‬

Effect of inhibitors of Ornithine decarboxylase on retrovirus induced transformation of murine erythroid precursors in vitro. Cancer Res 46:6246-6429 (1986)

Evolution of B cell lineage lymphomas in mice with a retrovirus-induced immunodeficiency syndrome MAIDS. J Immunol 140:1123-1131 (1987)

Hemopoietic lineage conversion: v-raf oncogene converts Eμ-myc transgenic B cells into macrophages.‬ Cell 53:857-867‬ (1988)

In vitro derived leukemic erythroid cell lines induced by a raf/myc retrovirus differentiate in response to erythropoietin. Proc Natl Acad Sci USA 85:8506-8510 (1988)

‪v-cbl, a new oncogene from a dual-recombinant murine retrovirus that induced early B-lineage lymphomas‬. Proc Natl Acad Sci USA 86:1168-1172 (1989)

Transformation of murine bone marrow cells with a raf/myc retrovirus yields clonally related mature B cells and macrophages. Mol Cell Biol 10:3562-3568 (1990)

Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphoma genesis in Eμ-myc transgenic mice. Cell 65:1-10‬ (1991)

‪Erythropoietin-induced stimulation of differentiation and proliferation in J2E cells is not mimicked by chemical induction‬. Blood 80:412-419‬ (1992)

‪A rapid fatal erythroleukemia caused by J2E cells can be treated ex vivo with erythropoietin‬. Leukemia 9:900-907‬ (1995)

Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E ‬ erythroid cells.‬ EMBO Journal 16:1610-1619‬ (1997)

HLS7, a hemopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1‬. EMBO Journal 18:5559-5566‬ (1999)

Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn‬. Cancer Res 61:2453-2458‬ (2001)

HLS5, a novel RBCC family member isolated from a hemopoietic lineage switch is a candidate tumour suppressor. J Biol Chem 279:8181-8189 (2004)

Myeloid Leukemia Factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. J Biol Chem 281:38791-38800 (2006)

Erythroid defects in TRa-/- mice. Blood 111: 3245-3248 (2008)

Hls5 regulates erythroid differentiation by modulating Gata-1 activity. Blood 111: 1946-1950 (2008)

Liar, a novel Lyn-binding nuclear/cytoplasmic shuttling protein that influences erythropoietin-induced differentiation. Blood 113: 3845-3856 (2009)

Gain-of-function Lyn induces anemia: appropriate Lyn activity is essential for normal erythropoiesis and Epo receptor signalling. Blood 122: 262-271 (2013)

A promoter level expression atlas. Nature 507:462-470 (2014)

Complementing tissue characterization by integrating transcriptome profiling from the Human Protein Atlas and from the FANTOM5 consortium'. NUCLEIC ACIDS RESEARCH, 43, pp. 6787-6798 (2015)

Transcriptional enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science 347:1010-1014 (2015) ‪